MILAN, April 21, 2023 /PRNewswire/ InSilicoTrials and AchilleS Vaccines have announced a strategic alliance that aims to unite visions, skills, experiences, the multidisciplinary collaboration
Press release content from Business Wire. The AP news staff was not involved in its creation.
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2
January 25, 2021 GMT
AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines)
KALKARA, Malta & SIENA, Italy (BUSINESS WIRE) Jan 25, 2021
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.